Form 4: InMed Pharmaceuticals Executive Exercises Stock Options
SEC Form 4 Filing
Eric C. Hsu, Sr. VP of Pre-Clinical Research and Development at InMed Pharmaceuticals, exercised employee stock options on May 27, 2024.
Summary
- Eric C. Hsu, a Senior VP at InMed Pharmaceuticals, exercised employee stock options.
- The transaction occurred on May 27, 2024.
- Mr. Hsu exercised options for 545 common shares at an exercise price of $263.18.
- Following the transaction, Mr. Hsu directly owns 52,000 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event, simply reflecting an executive exercising stock options. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is important for investor confidence.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 05/27/2019 | Date exercisable for Employee Stock Option |
| 05/27/2024 | Date of transaction: exercise of employee stock options and Expiration Date for Employee Stock Option |
| 05/28/2024 | Date of signature |
Keywords
InMed Pharmaceuticals, Stock Options, Form 4, Beneficial Ownership, Executive Compensation, Securities Exchange Act, Eric C. Hsu
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.